Epstein-Barr is among the most common viruses, but no vaccines are available to prevent its infection. Merck is joining the pursuit for a vaccine by striking a deal with Opko Health, paying $50 million…
Continue Reading
What You Should Know:– COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company.– GTC has a very innovative approach to genetic testing,…
Continue Reading
Transcarent, a digital platform focused on the self-insured employer market, announced plans to acquire assets from 98point6, including its AI-enabled virtual care platform and care business.According to reporting by Forbes, the deal is worth…
Continue Reading
Chroma Medicine, a biotech company developing therapies that turn genes on or off as a way of treating genetic disorders, has raised $135 million as it works to generate data that could show the…
Continue Reading
TALi obtains Australia’s nod for cognitive attention trainer deviceTALi Digital, an ASX-listed developer of diagnostic and therapeutic tools for improving children’s attention, has received the Therapeutic Goods Administration’s approval for its latest product, ReadyAttentionGo!
Available…
MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
Radiation is commonly employed in hospitals around the world to treat tumors, typically using gamma ray beams of high energy photons, with a relatively long range, that penetrate all the tissues on the way…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
As a health economist, researcher in evidence-based medicine, and consultant to biopharma executives, I am no stranger to data. We all want more of it, to make sense of it, and to use it…
Continue Reading
What You Should Know:– Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery…
Continue Reading
